G
Gregory A. Masters
Researcher at University of Chicago
Publications - 44
Citations - 3398
Gregory A. Masters is an academic researcher from University of Chicago. The author has contributed to research in topics: Chemotherapy & Lung cancer. The author has an hindex of 18, co-authored 44 publications receiving 2843 citations. Previous affiliations of Gregory A. Masters include Indiana University & University of Maryland, Baltimore.
Papers
More filters
Journal ArticleDOI
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli,Sherman Baker,Sarah Temin,William Pao,Timothy Aliff,Julie R. Brahmer,David H. Johnson,Janessa L. Laskin,Gregory A. Masters,Daniel T. Milton,Luke Nordquist,David G. Pfister,Steven Piantadosi,Joan H. Schiller,Reily Smith,Thomas J. Smith,John R. Strawn,David Trent,Giuseppe Giaccone +18 more
TL;DR: The scope of the guideline was narrowed to chemotherapy and biologic therapy, and recommendations for the treatment of patients with stage IV non-small-cell lung cancer were updated.
Journal ArticleDOI
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H. Hanna,Bryan J. Schneider,Sarah Temin,Sherman Baker,Julie R. Brahmer,Peter M. Ellis,Laurie E. Gaspar,Laurie E. Gaspar,Rami Y. Haddad,Paul J. Hesketh,Dharamvir Jain,Ishmael Jaiyesimi,David H. Johnson,Natasha B. Leighl,Tanyanika Phillips,Gregory J. Riely,Andrew G. Robinson,Rafael Rosell,Joan H. Schiller,Navneet Singh,David R. Spigel,Janis O. Stabler,Joan Tashbar,Gregory A. Masters +23 more
TL;DR: This guideline update reflects changes in evidence since the previous guideline update and is conditional on the basis of histology, PD-L1 status, and/or the presence of contraindications.
Journal ArticleDOI
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Jeffrey D. Bradley,Chen Hu,Ritsuko Komaki,Gregory A. Masters,George R. Blumenschein,Steven E. Schild,Jeffrey A. Bogart,Kenneth M. Forster,Anthony M. Magliocco,V.S. Kavadi,Samir Narayan,Puneeth Iyengar,Clifford G. Robinson,Raymond B. Wynn,Christopher Koprowski,Michael R. Olson,Joanne Meng,Rebecca Paulus,Walter J. Curran,Hak Choy +19 more
TL;DR: A 60-Gy radiation dose with concurrent chemotherapy should remain the standard of care, with the OS rate being among the highest reported in the literature for stage III NSCLC.
Journal ArticleDOI
CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation
Vinit Kumar,Pingyan Cheng,Thomas Condamine,Sridevi Mony,Lucia R. Languino,Judith C. McCaffrey,Neil G. Hockstein,Michael J. Guarino,Gregory A. Masters,Emily Penman,Fred Denstman,Xiaowei Xu,Dario C. Altieri,Hong Du,Cong Yan,Dmitry I. Gabrilovich +15 more
TL;DR: iteration of TAMs in tumor site from monocytic precursors was controlled by downregulation of the activity of the transcription factor STAT3, which has a unique function in the tumor environment in controlling the differentiation of MDSC into TAM.
Journal ArticleDOI
Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas.
Andrew Kowalczuk,Robert L Macdonald,Chris Amidei,Dohrmann G rd,Robert K. Erickson,Javad Hekmatpanah,Stuart A. Krauss,Swarna Krishnasamy,Gregory A. Masters,Sean Mullan,Arno J. Mundt,Patrick J. Sweeney,Everett E. Vokes,Bryce Weir,Robert Wollman +14 more
TL;DR: It is concluded that the most important prognostic factors affecting survival of patients with anaplastic astrocytomas and glioblastomas multiforme are tumor grade, age, preoperative performance status, and radiation therapy.